Specific Activities of Dolastatin 10 and Peptide Derivatives against Cryptococcus neoformans

The biosynthetic peptide dolastatin 10 is currently in phase I and II cancer clinical trials. We evaluated the antifungal spectrum of dolastatin 10 and four structural modifications. In broth macrodilution assays, the peptides were fungicidal for American Type Culture Collection strains and clinical...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Pettit, Robin K., Pettit, George R., Hazen, Kevin C.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1998
Assuntos:	Susceptibility
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC105973/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9797233/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.42.11.2961
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!